Morgan Stanley lowered the firm’s price target on 2seventy Bio (TSVT) to $5 from $6 and keeps an Equal Weight rating on the shares following 2Seventy Bio’s recent announcement to be acquired by Bristol Myers (BMY). The firm expects an on-time transaction close in Q2 at the proposed transaction price.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TSVT:
- Hold Rating Amidst Favorable Acquisition Terms and Competitive Pressures for 2seventy bio
- Spotify upgraded, Freshpet downgraded: Wall Street’s top analyst calls
- Morning Movers: 2seventy Bio skyrockets following acquisition by Bristol Myers
- 2seventy Bio downgraded to Market Perform from Outperform at Leerink
- 2seventy Bio to be acquired by Bristol Myers for $5.00 per share in cash